NEW YORK — Rosen Law Firm, a prominent legal entity specializing in investor rights, has issued a reminder to those who acquired securities from Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the period from November 2, 2023, to October 30, 2024. Investors are instructed to take note of a crucial upcoming deadline on March 10, 2025, for the appointment of the lead plaintiff in a class-action lawsuit concerning alleged securities fraud.
Investors who have purchased shares within this defined window, referred to as the Class Period, can potentially partake in compensation arrangements on a contingency basis. This means they would not be required to pay any out-of-pocket fees or costs.
Individuals looking to join the class action against Regeneron Pharmaceuticals can do so by reaching out to Phillip Kim, Esq. from Rosen Law Firm. A lawsuit has been filed already, and those interested in serving as lead plaintiff must petition the court by the March deadline. The lead plaintiff will act on behalf of other class members to direct the ongoing litigation.
Rosen Law Firm encourages shareholders to choose legal counsel judiciously, highlighting its track record of successful outcomes in similar lawsuits. The firm notes many competing firms may lack actual litigation experience in securities class actions, sometimes acting more as intermediaries. Rosen Law Firm itself has a robust global presence and focuses exclusively on securities class actions and shareholder derivative litigation.
Significantly, during this Class Period, the lawsuit alleges several counts of misconduct by Regeneron. Defendants are accused of making misleading statements and failing to disclose crucial information regarding the company’s dealings. Allegedly, Regeneron compensated distributors for not charging extra credit card fees to Eylea customers, effectively subsidizing and artificially lowering the price paid by consumers. Such actions allegedly gave Regeneron an unfair competitive advantage, inflated reported sales for Eylea, and resulted in a misstated Average Sales Price (ASP).
The repercussions of these actions, according to the lawsuit, led to a misrepresentation of the company’s business and operations. When details of these practices were publicly revealed, shareholders allegedly faced significant financial losses.
Shareholders are reminded that no class has yet been certified in this matter. Until such certification occurs, investors are not automatically represented by Rosen Law Firm unless they establish a direct agreement. Shareholders may also choose to do nothing at this time and still retain the possibility of participating in any future recoveries.
This legal alert follows Rosen Law Firm’s established history of securing notable settlements for investors, including a landmark securities class action settlement against a Chinese company and consistent high rankings by ISS Securities Class Action Services.
This article was created automatically by OpenAI, and details presented regarding people, facts, circumstances, and overall story could be inaccurate. If you require corrections, removals, or retractions of content, please contact contact@publiclawlibrary.org.